Next generation treatment of Pompe disease using systemic gene transfer with AAV9

Darin J. Falk, Barry J. Byrne(University of Florida), Thomas J. Conlon(Adelson Foundation), Jeffry S. Kelley(University of Florida), Sean Germain(University of Florida), Kirsten Erger(University of Florida), Meghan S. Soustek(University of Florida), Nathalie Clément(University of Florida), Denise A Cloutier(University of Florida), Cathryn Mah(Anna Needs Neuroblastoma Answers)
Molecular Genetics and Metabolism
January 18, 2011
10.1016/j.ymgme.2010.11.062
Cited by 0

Related Papers

Treatment of Leber Congenital Amaurosis Due to <i>RPE65</i> Mutations by Ocular Subretinal Injection of Adeno-Associated Virus Gene Vector: Short-Term Results of a Phase I Trial
|Human Gene Therapy|2008|950
Recombinant Adeno-Associated Virus Serotype 9 Leads to Preferential Cardiac Transduction In Vivo
|Circulation Research|2006|400
Mutational Analysis of the Adeno-Associated Virus Type 2 (AAV2) Capsid Gene and Construction of AAV2 Vectors with Altered Tropism
|Journal of Virology|2000|392
Sustained transgene expression despite T lymphocyte responses in a clinical trial of rAAV1-AAT gene therapy
|Proceedings of the National Academy of Sciences|2009|322
Human <i>RPE65</i> Gene Therapy for Leber Congenital Amaurosis: Persistence of Early Visual Improvements and Safety at 1 Year
|Human Gene Therapy|2009|312